BİSFOSFANAT KULLANIMINA BAĞLI ÇENE KEMİĞİNDE GELİŞEN OSTEONEKROZ: ETYOLOJİ, RİSK FAKTÖRLERİ, TANI KRİTERLERİ VE TEDAVİ ALTERNATİFLERİ

1. Font RF, Garcia ML, Martinez JMO.
Osteochemonecrosis of the Jaws due to
Bisphosphonate treatments: Update. Med Oral
Patol Oral Cir Bucal 2008; 13: 318-24.
2. Fleisch H. Development of bisphosphonates. Breast
Cancer Res 2002; 4: 30-4.
3. Crépin S, Laroche ML, Sarry B, Merle L.
Osteonecrosis of the jaw induced by clodronate, an
alkylbiphosphonate: case report and literature
review. Eur J Clin Pharmacol 2010; 66: 547-54.
4. Merigo E, Manfredi M, Meleti M, et al. Bone
necrosis of the jaws associated with
bisphosphonate treatment: a report of twenty-nine
cases. Acta Biomed 2006; 77: 109-17.
5. Leite AF, Figueiredo PT, Melo NS, Acevedo AC,
Cavalcanti MG, Paula LM, Paula AP, Guerra EN.
Bisphosphonateassociated osteonecrosis of the
jaws. Report of a case and literature review. Oral
Surg Oral Med Oral Pathol Oral Radiol Endod 2006;
102: 14-21.
6. Katz H. Endodontic Implications of Biphosphonate-
Associated Osteonecrosis of the Jaws: A Report of
Three Cases. J Endod 2005; 31: 831-34.
7. Sparidans RW, Twiss IM, Talbot S.
Bisphosphonates in bone diseases. Pharm World
Sci 1998; 20: 206–13.
8. Reszka AA, Rodan GA. Mechanism of action of
bisphosphonates. Curr Osteoporos Rep 2003;1:
45–52.
9. Reszka AA, Rodan GA. Nitrogen-containing
bisphosphonate mechanism of action. Mini Rev
Med Chem 2004; 4: 711–19.
10. Murakami H, Takahashi N, Sasaki T, Udagawa N,
Tanaka S, Nakamura I, Zhang D, Barbier A, Suda
T. A possible mechanism of the specific action of
bisphosphonates on osteoclasts: tiludronate
preferentially affects polarized osteoclasts having
ruffled borders. Bone 1995; 17: 137-44.
11. Naidu A, Dechow PC, Spears R, Wright JM, Kessler
HP, Opperman LA. The effects od bisphosphonates
on osteoblasts in vitro. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod 2008; 106: 5-13.
12. Delmas PD, Recker RR, Chesnut CH III, et al. Daily
and intermittent oral ibandronate normalize bone
turnover and provide significant reduction in
vertebral fracture risk: Results from the BONE
study. Osteoporos Int 2004;15: 792-8.
13. Roelofs AJ, Thompson K, Gordon S, Rogers MJ.
Molecular mechanisms of action of
bisphosphonates: Current status. Clin Cancer Res
2006; 12: 62225-305.
14. Pazianas M, Miller P, Blumentals WA, Bernal M,
Kothawala P. A review of the literature on
osteonecrosis of the jaw in patients with
osteoporosis treated with oral bisphosphonates:
prevalence, risk factors, and clinical characteristics.
Clin Ther 2007; 29: 1548-58.
15. Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical
management of Paget's disease of bone: indication
for treatment and review of current therapies. J
Bone Miner Res 2006; 21(Suppl 2): 94-8.
16. Hosking D, Lyles K, Brown JP, et al. Long-term
control of bone turnover in Paget's disease with
zoledronic acid and risedronate. J Bone Miner Res
2007; 22: 142-8.
17. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P,
Grötz KA. Incidence of bisphosphonate-associated
osteonecrosis of the jaws in breast cancer patients.
Cancer 2009 15; 115: 1631-7.
18. Walter C, Al-Nawas B, Grötz KA, Thomas C,
Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.
Prevalence and risk factors of bisphosphonateassociated
osteonecrosis of the jaw in prostate
cancer patients with advanced disease treated with
zoledronate. Eur Urol 2008; 54: 1066-72.
19. American Dental Association Council on Scientific
Affairs. Dental management of patients receiving
oral bisphosphonate therapy: Expert panel
recommendations. J Am Dent Assoc 2006;
137:1144–50.
Atatürk Üniv. Diş Hek. Fak. Derg. SOĞUR, ÖNEM, BAKSI,
J Dent Fac Atatürk Uni
Cilt:22, Sayı: 1, Yıl: 2012, Sayfa: 83-95
92
20. Rauch F, Glorieux FH. Osteogenesis imperfecta.
Lancet 2004; 363: 1377-85.
21. Kamoun-Goldrat A, Ginisty D, Merrer M. Effect of
bisphosphonates on tooth eruption in children with
osteogenesis imperfecta. Eur J Oral Sci 2008; 116:
195-8.
22. Reid IR, Bolland MJ, Grey AB. Is
bisphosphonateassociated osteonecrosis of the jaw
caused by soft tissuetoxicity? Bone 2007; 41: 318-
20.
23. Landesberg R, Cozin M, Cremers S, Woo V,
Kousteni S,Sinha S, Garrett-Sinha L, Raghavan S.
Inhibition of Oral Mucosal Cell Wound Healing by
Bisphosphonates. J Oral Maxillofac Surg 2008; 66:
839-47.
24. Marx RE. Pamidronate (Aredia) and zoledronate
(Zometa) induced avascular necrosis of the jaws: a
growing epidemic. J Oral Maxillofac Surg 2003; 61:
1115-7.
25. Ruggiero SL, Mehrotra B, Rosenberg T, Engroff,
SL. Osteonecrosis of the jaws associated with the
use of bisphosphonates: a review of 63 cases. J
Oral Maxillofac Surg 2004; 62: 527-34.
26. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian
MA, Sanchis JM, Silvestre FJ, Scully C. Avascular
jaw osteonecrosis in association with cancer
chemotherapy: series of 10 cases. J Oral Pathol
2005; 34: 120-3.
27. Carneiro E, Vibhute P, Montazem A, Som PM.
Bisphosphonate-associated mandibular
osteonecrosis. AJNR Am J Neuroradiol 2006; 27:
1096-7.
28. Mortensen M, Lawson W, Montazem A.
Osteonecrosis of the jaw associated with
bisphosphonate use: Presentation of seven cases
and literature review. Laryngoscope 2007;117: 30-
4.
29. Friedrich RE, Blake FA. Avascular mandibular
osteonecrosis in association with bisphosphonate
therapy: a report on four patients. Anticancer Res
2007; 27: 1841-5.
30. Stumpe MR, Chandra RK, Yunus F, Samant S.
Incidence and risk factors of bisphosphonateassociated
osteonecrosis of the jaws. Head Neck.
2009; 31: 202-6.
31. Junquera L, Gallego L, Cuesta P, Pelaz A, de
Vicente JC. Clinical experiences with
bisphosphonate-associated osteonecrosis of the
jaws: analysis of 21 cases. Am J Otolaryngol 2009;
30: 390-5.
32. Bedogni A, Bettini G, Totola A, Saia G, Nocini PF.
Oral bisphosphonate-associated osteonecrosis of
the jaw after implant surgery: a case report and
literature review. J Oral Maxillofac Surg 2010; 68:
1662-6.
33. Phal PM, Myall RW, Assael LA, Weissman JL.
Imaging findings of bisphosphonate-associated
osteonecrosis of the jaws. Am J Neuroradiol 2007;
28: 1139-45.
34. Badros A, Weikel D, Salama A et al. Osteonecrosis
of the jaw in multiple myeloma patients: clinical
features and risk factors. J Clin Oncol 2006; 24:
945–952.
35. Woo SB, Hellstein JW, Kalmar JR. Bisphosphonates
and osteonecrosis of the jaws. Ann Intern Med
2006; 144: 753-61.
36. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis
MJ. Incidence of osteonecrosis of the jaw in
patients with multiple myeloma and breast or
prostate cancer on intravenous bisphosphonate
therapy. J Oral Maxillofac Surg 2007; 65: 1328–
1331.
37. Ruggiero SL, Dodson TB, Assael LA, Landesberg R,
Marx RE, Mehrotra B. Task Force on
Bisphosphonate-Related Osteonecrosis of the
Jaws, American Association of Oral and
Maxillofacial Surgeons. American Association of
Oral and Maxillofacial Surgeons position paper on
bisphosphonate-related osteonecrosis of the jaw-
2009 update. Aust Endod J 2009; 35: 119-30.
38. Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo
Muzio L, Fulfaro F, Badalamenti G, Russo A,
Gebbia N. Bisphosphonate-related osteonecrosis of
the jaw (BRONJ): run dental management designs
and issues in diagnosis. Ann Oncol 2007; 18: 168-
72.
39. Bamias A, Kastritis E, Bamia C, Moulopoulos LA,
Melakopoulos I, Bozas G, Koutsoukou V, Gika D,
Anagnostopoulos A, Papadimitriou C, Terpos E,
Dimopoulos MA. Osteonecrosis of the jaw in cancer
after treatment with bisphosphonates: incidence
and risk factors. J Clin Oncol 2005; 23: 8580-7.
40. Üstün Y, Erdoğan Ö. Çene kemiklerinin
bisfosfonatlara bağlı osteonekrozunda teşhis ve
tedavi yaklaşımları. ADO Klinik Bilimler Dergisi
2007; 1: 37- 42.
Atatürk Üniv. Diş Hek. Fak. Derg. SOĞUR, ÖNEM, BAKSI,
J Dent Fac Atatürk Uni
Cilt:22, Sayı: 1, Yıl: 2012, Sayfa: 83-95
93
41. Mavrokokki T, Cheng A, Stein B, et al. Nature and
frequency of bisphosphonate-associated
osteonecrosis of the jaws in Australia. J Oral
Maxillofac 2007; 65: 415-23.
42. Durie BG, Katz M, Crowley J. Osteonecrosis of the
jaw and bisphosphonates. N Engl J Med 2005;
353: 99-102.
43. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi
P: Jaw bone necrosis without previous dental
extractions associated with the use of
bisphosphonates (pamidronate and zoledronate): a
four-case report. J Oral Pathol Med 2005; 34: 613-
761.
44. Ruggiero SL, Fantasia J, Carlson E.
Bisphosphonate-related osteonecrosis of the jaw:
background and guidelines for diagnosis, staging
and management. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod 2006; 102: 433–41.
45. Zervas K, Verrou E, Teleioudis Z et al. Incidence,
risk factors and management of osteonecrosis of
the jaw in patients with multiple myeloma: a
single-centre experience in 303 patients. Br J
Haematol 2006; 134: 620–3.
46. Marx RE, Sawatari Y, Fortin M, Braumand V.
Bisphosphonate -induced exposed bone
(Osteonecrosis /osteopetrosis) of the jaws: risk
factors, recognition, prevention, and treatment.
Journal of Oral Maxillofacial Surgery 2005: 63;
1567-75.
47. Vassiliou V, Tselis N, Kardamakis D. Osteonecrosis
of the jaws - clinicopathologic and radiologic
characteristics, preventive and
therapeuticstrategies. Strahlenther Onkol
2010;186: 367–73.
48. Ergün S, Güneri P, Koca H. Çene kemiklerinin yeni
tehlikesi: bisfosfonatlar. Cumhuriyet Üniversitesi
Diş Hekimliği Fakültesi Dergisi 2008; 11: 140-5.
49. Soydan SS, Veziroğlu Şenel F, Araz K. Bifosfonata
bağlı olarak çene kemiklerinde gelişen
osteonekrozun patogenezi ve tedavisi. Hacettepe
Diş Hekimliği Fakültesi Dergisi 2009; 33: 61-8.
50. Khan AA, Sándor GKB, Dore E, Morrison AD, Alsahli
M, Amin F, et al. Canadian consensus practice
guidelines for bisphosphonate associated
osteonecrosis of the jaw. J Rheumatol 2008; 35:
1391–7.
51. Bagán J, Blade J, Cozar JM, Constela M, García
Sanz R, Gómez Veiga G, et al. Recommendations
for the prevention, diagnosis, and treatment of
osteonecrosis of the jaw (ONJ) in cancer patients
treated with bisphosphonates. Med Oral Patol Oral
Cir Bucal 2007; 12: E336–40.
52. Tubiana-Hulin M, Spielmann M, Roux C, Campone
M, Zelek L, Gligorov J, et al. Physiopathology and
management of osteonecrosis of the jaws related
to bisphosphonate therapy for malignant bone
lesions. A French expert panel analysis. Crit Rev
Oncol Hematol 2009; 71: 12–21.
53. British Dental Association. Bisphosphonates fact
file. London: British Dental Association; 2008. URL:
http://www.bda.org.
54. Advisory Task Force on Bisphosphonate-Related
Osteonecrosis of the Jaws, American Association of
Oral and Maxillofacial Surgeons. American
Association of Oral and Maxillofacial Surgeons
position paper on bisphosphonate-related
osteonecrosis of the jaws. J Oral Maxillofac Surg
2007; 65: 369-76.
55. Colella G, Campisi G, Fusco V. American
Association of Oral and Maxillofacial Surgeons
position paper: Bisphosphonaterelated
osteonecrosis of the jaws—2009 update: the need
to refine the BRONJ definition. J Oral Maxillofac
Surg 2009; 67: 2698–9.
56. Stockmann P, Hinkmann FM, Lell MM, Fenner M,
Vairaktaris E, Neukam FW, Nkenke E. Panoramic
radiograph, computed tomography or magnetic
resonance imaging. Which imaging technique
should be preferred in bisphosphonate-associated
osteonecrosis of the jaw? A prospective clinical
study. Clin Oral Investig 2010; 14: 311-7.
57. Bisdas S, Chambron Pinho N, Smolarz A, Sader R,
Vogl TJ, Mack MG. Biphosphonate-induced
osteonecrosis of the jaws: CT and MRI spectrum of
findings in 32 patients. Clin Radiol 2008; 63: 71–7.
58. Bedogni A, Blandamura S, Lokmic Z, Palumbo C,
Ragazzo M, Ferrari F, et al. Bisphosphonateassociated
jawbone osteonecrosis: a correlation
between imaging techniques and histopathology.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
2008; 105: 358–64.
59. Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli
F, Di Lenarda R. Bone scintigraphy and SPECT/CT
of bisphosphonate-induced osteonecrosis of the
jaw. J Nucl Med 2009; 50: 30-5.
Atatürk Üniv. Diş Hek. Fak. Derg. SOĞUR, ÖNEM, BAKSI,
J Dent Fac Atatürk Uni
Cilt:22, Sayı: 1, Yıl: 2012, Sayfa: 83-95
94
60. Elad S, Gomori MJ, Ben-Ami N, Friedlander-
Barenboim S, Regev E, Lazarovici TS, Yarom N.
Bisphosphonate-related osteonecrosis of the jaw:
clinical correlations with computerized tomography
presentation. Clin Oral Investig 2010; 14: 43-50.
61. Chiandussi S, Biasotto M, Dore F, et al. Clinical and
diagnostic imaging of bisphosphonate-associated
osteonecrosis of the jaws. Dentomaxillofac Radiol
2006; 35: 236–43.
62. Bianchi SD, Scoletta M, Cassione FB, Migliaretti G,
Mozzati M. Computerized tomographic findings in
bisphosphonate-associated osteonecrosis of the
jaw in patients with cancer. Oral Surg Oral Med
Oral Pathol Oral Radiol Endod 2007;104: 249-58.
63. Barragan-Adjemian C, Lausten L, Ang DB, Johnson
M, Katz J, Bonewald LF.Bisphosphonate-related
osteonecrosis of the jaw: model and diagnosis with
cone beam computerized tomography. Cells
Tissues Organs 2009; 189: 284-8.
64. Singer SR, Mupparapu M. Plain film and CBCT
findings in a case of bisphosphonate-related
osteonecrosis of the jaw. Quintessence Int 2009;
40: 163-5.
65. Hino S, Murase R, Terakado N, et al. Response of
diffuse sclerosing osteomyelitis of the mandible to
alendronate: follow-up study by 99mTc
scintigraphy. Int J Oral Maxillofac Surg 2005; 34:
576–78.
66. van der Waal RI, Buter J, van der Waal I. Oral
metastases: report of 24 cases. Br J Oral Maxillofac
Surg 2003; 41: 3–6.
67. Studer G, Gratz KW, Glanzmann C.
Osteoradionecrosis of the mandibula in patients
treated with different fractionations. Strahlenther
Onkol 2004; 180: 233–40.
68. Studer G, Studer SP, Zwahlen RA, et al.
Osteoradionecrosis of the mandible: minimized risk
profile following intensity-modulated radiation
therapy (IMRT). Strahlenther Onkol 2006; 182:
283–8.
69. Brenner DJ, Hall EJ. Computed tomography—an
increasing source of radiation exposure. N Engl J
Med 2007; 357: 2277-8.
70. Treister NS, Friedland B, Woo SB. Use of conebeam
computerized tomography for evaluation of
bisphosphonate-associated osteonecrosis of the
jaws.Oral Surg Oral Med Oral Pathol Oral Radiol
Endod 2010; 109:753-64.
71. Schulze D, Blessmann M, Pohlenz P, Wagner KW,
Heiland M.Diagnostic criteria for the detection of
mandibular osteomyelitis using cone-beam
computed tomography. Dentomaxillofac Radiol
2006; 35: 232-5.
72. Kumar V, Pass B, Guttenberg SA, Ludlow J, Emery
RW, Tyndall DA, et al. Bisphosphonate-related
osteonecrosis of the jaws: a report of three cases
demonstrating variability in outcomes and
morbidity. J Am Dent Assoc 2007; 138: 602-9.
73. Fullmer JM, Scarfe WC, Kushner GM, Alpert B,
Farman AG. Cone beam computed tomographic
findings in refractory chronic suppurative
osteomyelitis of the mandible. Br J Oral Maxillofac
Surg 2007; 45: 364-71.
74. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos
I, Gika D, Roussou M, Migkou M, Eleftherakis-
Papaiakovou E, Christoulas D, Terpos E, Bamias A.
Reduction of osteonecrosis of the jaw (ONJ) after
implementation of preventive measures in patients
with multiple myeloma treated with zoledronic
acid. Ann Oncol 2009; 20: 117-20.
75. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E,
Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi
E. Decreased occurrence of osteonecrosis of the
jaw after implementation of dental preventive
measures in solid tumour patients with bone
metastases treated with bisphosphonates. The
experience of the National Cancer Institute of
Milan. Ann Oncol 2009; 20: 137-45.
76. Rosen HN, Moses AC, Garber J et al. Serum CTX: a
new marker of bone resorption that shows
treatment effect more often than other markers
because of a low coefficient of variability and large
changes with bisphosphonate therapy. Calcif
Tissue Int 2000; 66: 100.
77. Yarom N, Lazarovici TS, Elad S. Oral
bisphosphonate-related osteonecrosis of the jaw:
incidence, clinical features, prevention, and
treatment recommendations. Clinic Rev Bone Miner
Metab 2010: 8; 27–31.
78. Bone HG, Hosking D, Devogelaer JP et al. Ten
years’ experience with alendronate for
osteoporosis in postmenopausal women. N Engl J
Med 2004; 350: 1189.
79. Bagan JV, Jimenez Y, Murillo J et al. Jaw
osteonecrosis associated with bisphosphonates:
multiple exposed areas and its relationship to teeth
Atatürk Üniv. Diş Hek. Fak. Derg. SOĞUR, ÖNEM, BAKSI,
J Dent Fac Atatürk Uni
Cilt:22, Sayı: 1, Yıl: 2012, Sayfa: 83-95
95
extractions. Study of 20 cases (Letter). Oral Oncol
2006; 42: 327.
80. Carlson EC. The role of surgical resection in the
management of bisphosphonate-related
osteonecrosis of the jaws. J Oral Maxillofac Surg
2009; 67.
81. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonates
induced osteonecrosis: risk factors, prediction of
risk using serum CTX testing, prevention, and
treatment. J Oral Maxillofac Surg 2007; 65: 2397.
82. Kademani D, Koka S, Lacy MQ, Rajkumar V.
Primary surgical therapy for osteonecrosis of the
jaw secondary to bisphosphonate therapy. Mayo
Clin Proc 2006; 81: 1100.
83. Freiberger JJ. The utility of hyperbaric oxygen in
the treatment of bisphosphonate-related
osteonecrosis of the jaws. J Oral Maxillofac Surg
2009; 67(5 Suppl.):96–106.
84. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft
KH, Boneta O, Moon RE, et al. Hyperbaric oxygen
treatment and bisphosphonateinduced
osteonecrosis of the jaw; a case series. J Oral
Maxillofac Surg 2007; 65: 1321–7.
85. Lee CY, David T, Nishime M. Use of platelet-rich
plasma in the management of oral
bisphosphonate-associated osteonecrosis of the
jaw: a report of two cases. J Oral Implantol 2007;
33: 371-382.
86. Harper RP, Fung E. Resolution of bisphosphonateassociated
osteonecrosis of the mandible: possible
application for intermittent low dose parathyroid
hormone [rhPTH(1-34)]. J Oral Maxillofac Surg
2007; 65: 573–80.
87. Curi MM, Cossolin GSI, Koga DH, Araújo SR, Feher
O, dos Santos MO, et al. Treatment of avascular
osteonecrosis of the mandible in cancer patients
with a history of bisphosphonate therapy by
combining bone resection and autologous plateletrich
plasma: report of 3 cases. J Oral Maxillofac
Surg 2007; 65: 349–55.
88. Vescovi P, Merigo E, Meleti M, Fornaini C,
Nammour S, Manfredi M. Nd:YAG laser
biostimulation of bisphosphonate-associated
necrosis of the jawbone with and without surgical
treatment. Br J Oral Maxillofac Surg 2007;45: 628–
32.
89. Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G.
Ozone therapy in the treatment of avascular
bisphosphonate-related jaw osteonecrosis. J
Craniofac Surg 2007; 18: 1071–5.
90. Stübinger S, Dissmann JP, Pinho NC, Saldamli B,
Seitz O, Sader R. A preliminary report about
treatment of bisphosphonate related osteonecrosis
of the jaw with Er:YAG laser ablation. Lasers Surg
Med 2009; 41: 26–30.
91. McLeod NM, Patel V, Kusanale A, Rogers SN,
Brennan PA. Bisphosphonate osteonecrosis of the
jaw: a literature review of UK policies versus
international policies on the management of
bisphosphonate osteonecrosis of the jaw. Br J Oral
Maxillofac Surg 2011; 49: 335-42.
92. Yarom N, Yahalom R, Shoshani Y, Hamed W,
Regev E, Elad S. Osteonecrosis of the jaw induced
by orally administered bisphosphonates: incidence,
clinical features, predisposing factors and
treatment outcome. Osteoporos Int 2007; 18:
1363-70.